# ScieHome

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sciehome

- Industry: Medical Devices & Equipment
- Headquarters: Shanghai, China
- Latest round: Series A (May 21, 2026)
- Investors on record: 1

## About

Based in Shanghai, China and founded in 2022, Shanghai SciHonic Life Sciences Co., Ltd., trading as ScieHome, is a medical device company dedicated to creating a platform of scientific and technological innovation centered around interventional ultrasound and drug-device combination technologies. The founding team of the company has experience in ultrasound energy R&D, drug-device technology synergy and so on, with over 10 years of executive positions and work experience at companies such as MicroPort Medical and Philips Medical. It's founder, Mr. Wu Changsheng, is a former project leader for the Firehawk drug-eluting stent system at MicroPort Medical. In May 2026, ScieHome raised a Series A funding from Efung Capital.

The company focuses on the development and provision of innovative energy device products that solve clinical challenges. It has established a series of technological platforms, including interventional ultrasound energy technology, drug-device combination technology, software and algorithm architecture technology, etc. Its first core product, the SciHonic ultrasound-assisted thrombolysis system, is based on multidisciplinary underlying technology accumulation and is designed to closely align with clinical scenarios, currently in the registration clinical stage.

The company generates revenue by developing and commercializing interventional ultrasound medical devices and integrated therapeutic solutions.

The Series A funding raised in May 2026 will be used to further accelerate the commercialization of the company's innovative ultrasound energy devices, solidify its core technological barrier in drug-acoustic synergy, and comprehensively build ScieHome's innovative ultrasound ecosystem of "ultrasound energy, drug-acoustic synergy, and precision diagnosis and treatment".

## Funding rounds

- Series A, May 21, 2026 — Efung Capital

## Investors

- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series A